Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Eiger BioPharmaceuticals (STU:72C) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2023, Eiger BioPharmaceuticals has a Sloan Ratio of -192.94%, indicating earnings are more likely to be made up of accruals.
Eiger BioPharmaceuticals Sloan Ratio % Related Terms
Eiger BioPharmaceuticals Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:72C vs EDSA, SIGY, EVLO: Sloan Ratio % Comparison
For the Biotechnology subindustry, Eiger BioPharmaceuticals's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiger BioPharmaceuticals Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Eiger BioPharmaceuticals's Sloan Ratio % falls into.
Eiger BioPharmaceuticals Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Eiger BioPharmaceuticals's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Eiger BioPharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -40.131 (Jun. 2023 ) + -28.871 (Dec. 2023 ) = €-69.00 Mil.
Eiger BioPharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -42.495 (Jun. 2023 ) + -26.142 (Dec. 2023 ) = €-68.64 Mil.
Eiger BioPharmaceuticals's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 39.9 (Jun. 2023 ) + 28.426 (Dec. 2023 ) = €68.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eiger BioPharmaceuticals (STU:72C) has a Sloan Ratio % of -192.94% as of Dec. 2023. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Eiger BioPharmaceuticals and its competitors.
Is Eiger BioPharmaceuticals' Sloan Ratio % too high?
Eiger BioPharmaceuticals' current Sloan Ratio % is -192.94%. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' Sloan Ratio % compare to EDSA and SIGY?
Eiger BioPharmaceuticals' Sloan Ratio % of -192.94% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current Sloan Ratio % is -192.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current Sloan Ratio % of -192.94%. The current Sloan Ratio % is -192.94%. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Sloan Ratio % is -192.94% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score
Get the complete analysis for STU:72C
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:72C has been successfully added to your 
